Association of Vitamin K Status with Arterial Calcification and Stiffness in Chronic Kidney Disease: The Chronic Renal Insufficiency Cohort

Arterial calcification and stiffness are common in people with chronic kidney disease (CKD). Higher vitamin K status has been associated with less arterial calcification and stiffness in CKD in cross-sectional studies. To determine the association of vitamin K status with coronary artery calcium (CA...

Full description

Saved in:
Bibliographic Details
Published in:Current developments in nutrition 2023-01, Vol.7 (1), p.100008-100008, Article 100008
Main Authors: Shea, M. Kyla, Wang, Jifan, Barger, Kathryn, Weiner, Daniel E., Townsend, Raymond R., Feldman, Harold I., Rosas, Sylvia E., Chen, Jing, He, Jiang, Flack, John, Jaar, Bernard G., Kansal, Mayank, Booth, Sarah L.
Format: Article
Language:English
Subjects:
arterial calcification
arterial stiffness
chronic kidney disease
matrix gla protein
Original Research
vascular calcification
vitamin K
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Arterial calcification and stiffness are common in people with chronic kidney disease (CKD). Higher vitamin K status has been associated with less arterial calcification and stiffness in CKD in cross-sectional studies. To determine the association of vitamin K status with coronary artery calcium (CAC) and arterial stiffness [pulse wave velocity (PWV)] at baseline and over 2–4 follow-up years in adults with mild-to-moderate CKD. Participants (n = 2722) were drawn from the well-characterized Chronic Renal Insufficiency Cohort. Two vitamin K status biomarkers, plasma phylloquinone and plasma dephospho-uncarboxylated matrix gla protein [(dp)ucMGP], were measured at baseline. CAC and PWV were measured at baseline and over 2–4 y of follow-up. Differences across vitamin K status categories in CAC prevalence, incidence, and progression (defined as ≥100 Agatston units/y increase) and PWV at baseline and over follow-up were evaluated using multivariable-adjusted generalized linear models. CAC prevalence, incidence, and progression did not differ across plasma phylloquinone categories. Moreover, CAC prevalence and incidence did not differ according to plasma (dp)ucMGP concentration. Compared with participants with the highest (dp)ucMGP (≥450 pmol/L), those in the middle category (300–449 pmol/L) had a 49% lower rate of CAC progression (incidence rate ratio: 0.51; 95% CI: 0.33, 0.78). However, CAC progression did not differ between those with the lowest (
ISSN:2475-2991
2475-2991
DOI:10.1016/j.cdnut.2022.100008